NPI-2358 (Plinabulin)|2mg|K1319-上海高创化学科技有限公司

SKU:K1319		M. Wt:336.39
Formula:C19H20N4O2		Solubility:No
Purity:>99%		Storage:2 years at -20 degrees centigrade
CAS No.:714272-27-2		Synonyms:N/A
Chemical NameN/A

Description	NPI-2358 (Plinabulin)
Targets
IC50	N/A
In vitro	Plinabulin(NPI-2358), a potent antimicrotubule, is a synthetic analog of NPI-2350. NPI-2358 binds to the colchicine-binding site of tubulin. NPI-2358 has potent in-vitro anti-tumor activity against various human tumor cell lines and maintains activity against tumor cell lines with various multidrug-resistant (MDR) profiles. NPI-2358 dose dependently increases HUVEC monolayer permeability--an in-vitro model of tumor vascular collapse. NPI-2358 in HUVECs was more potent than either colchicine or vincristine.
In vivo	At the RP2D of 30 mg/m?, plinabulin showed a favorable safety profile, while eliciting biological effects as evidenced by decreases in tumor blood flow, tumor pain, and other mechanistically relevant adverse events Plinabulin (7.5 mg/kg) significantly reduced the initial area under curve (IAUC) and the transfer constant (K(trans)) within 1 hour after injection. No significant anti-tumour effects were observed in the C3H tumours until doses of 12.5 mg/kg were achieved, but started at 1.5 mg/kg in the KHT sarcoma.
Clinical Trials	N/A
Features	N/A

Description

NPI-2358 (Plinabulin)

Targets

IC50

N/A

In vitro

Plinabulin(NPI-2358), a potent antimicrotubule, is a synthetic analog of NPI-2350. NPI-2358 binds to the colchicine-binding site of tubulin. NPI-2358 has potent in-vitro anti-tumor activity against various human tumor cell lines and maintains activity against tumor cell lines with various multidrug-resistant (MDR) profiles. NPI-2358 dose dependently increases HUVEC monolayer permeability--an in-vitro model of tumor vascular collapse. NPI-2358 in HUVECs was more potent than either colchicine or vincristine.

In vivo

At the RP2D of 30 mg/m?, plinabulin showed a favorable safety profile, while eliciting biological effects as evidenced by decreases in tumor blood flow, tumor pain, and other mechanistically relevant adverse events Plinabulin (7.5 mg/kg) significantly reduced the initial area under curve (IAUC) and the transfer constant (K(trans)) within 1 hour after injection. No significant anti-tumour effects were observed in the C3H tumours until doses of 12.5 mg/kg were achieved, but started at 1.5 mg/kg in the KHT sarcoma.

Clinical Trials

N/A

Features

N/A

工商信息

企业名称

上海高创化学科技有限公司

企业信息已认证

企业类型

信用代码

310228001353263

成立日期

2010-06-05

注册资本

经营范围

从事化学科技、计算机领域内技术开发、技术咨询、技术服务,从事生物科技领域内技术开发、技术咨询,化学试剂、化工原料及产品(除危险化学品、监控化学品、烟花爆竹、民用爆炸物品、易制毒化学品),实验室设备(除医疗器械),仪器仪表,Ⅰ类医疗器械,金属制品,电子产品,机电产品销售。【依法须经批准的项目,经相关部门批准后方可开展经营活动】

NPI-2358 (Plinabulin)由上海高创化学科技有限公司为您提供，货号K1319，规格：2mg，CAS号：714272-27-2，如您想了解更多关于NPI-2358 (Plinabulin)价格、NPI-2358 (Plinabulin)结构式、批发、用途等信息，欢迎咨询。除供应NPI-2358 (Plinabulin)外，还可为您提供热灭活胎牛血清（澳大利亚）、超级新生牛血清（无噬菌体低内毒素）、热灭新生牛血清（新西兰）等试剂，公司有专业的客户服务团队，是您值得信赖的合作伙伴，上海高创客户服务电话，售前、售后均可联系。